Latest news for  (OTC:MRAEF) Stock

CVR Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVI#NYSE">CVI</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.22) by 140.91 percent. This is a 94.51 percent decrease over earnings of $1.64 per share from the same period last year. The company reported quarterly sales of $1.967 billion which beat the analyst consensus estimate of $1.796 billion by 9.54 percent. This is a 12.03 percent decrease over sales of $2.236 billion the same period last year.

Earnings

Earnings Beats

News

CVR Energy Q2 2024 Adj. EPS $0.09 Beats $(0.22) Estimate, Sales $1.967B Beat $1.796B Estimate

WIIM

Woodward shares are trading lower after the company reported mixed Q3 financial results and lowered its FY24 revenue guidance below estimates.

Flowserve (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.63 by 15.87 percent. This is a 40.38 percent increase over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $1.16 billion which beat the analyst consensus estimate of $1.13 billion by 2.38 percent. This is a 7.12 percent increase over sales of $1.08 billion the same period last year.

Flowserve Q2 Adj $0.73 Beats $0.63 Estimate, Sales $1.16B Beat $1.13B Estimate

CIBC analyst Hamir Patel maintains West Fraser Timber (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WFG#TSX">WFG</a>) with a Outperformer and raises the price target from C$125 to C$138.

Price Target

Analyst Ratings

TSX:WFG

CIBC Maintains Outperformer on West Fraser Timber, Raises Price Target to C$138

Editor&#8217;s note: The new license allows DEMECAN to increase its annual yield by 2 tons with no specified limit as opposed to increasing its total quantity.
Under Germany&#8217;s new Medical Cannabis Law (MedCanG), DEMECAN has received a license that allows it to double its production capacity, resulting in an additional yield of approximately two tons annually. Although the license specifies this increase, it does not impose a strict limit on the total amount of cannabis that can be cultivated. Therefore, while the practical increase is by two tons, the potential for unlimited cultivation exists depending on the company's production capabilities, <a href="https://www.diesachsen.de/en/salud/new-law-allows-demecan-to-grow-more-cannabis-2942812" target="_blank" rel="noreferrer noopener">according to</a> DieSachsen.De. 
Partial cannabis legalization <a href="https://www.benzinga.com/markets/cannabis/24/04/38023610/heres-what-you-need-to-know-about-weed-legalization-in-germany-that-just-took-effect" target="_blank" rel="noreferrer noopener">took effect in Germany on April 1</a>, allowing adults over 18 to possess up to 25 grams of dried cannabis and cultivate up to three plants at home.
Canadian marijuana giant, Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) also confirmed last week that its German cannabis cultivation facility, Aphria RX GmbH, has <a href="https://www.benzinga.com/markets/cannabis/24/07/39889867/tilray-will-quintuple-its-medical-marijuana-production-in-germany-with-new-cultivation-license" target="_blank" rel="noreferrer noopener">obtained the first new cannabis cultivation license</a> issued in Germany. Another publicly traded Canadian company, Aurora Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>), is the <a href="https://www.benzinga.com/markets/cannabis/24/07/39975901/aurora-ramps-up-medical-cannabis-production-in-germany-with-enhanced-licenses-to-expand-portfoli" target="_blank" rel="noreferrer noopener">third to obtain the same license</a>.
In 2019, these three companies won a tender from the Federal Institute for Drugs and Medical Devices (BfArM), under which they were allowed to cultivate a limited amount of medical cannabis. Furthermore, the cannabis grown in Germany could only be sold to pharmacies via the state cannabis agency. Now, this intermediate step is no longer necessary.
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/04/38297284/another-cannabis-pioneer-expands-in-germany-via-acquisition-as-experts-say-theres-no-stepping-ba" target="_blank" rel="noreferrer noopener"> Another Cannabis Pioneer Expands In Germany Via Acquisition As Experts Say &#8216;There&#8217;s No Stepping Back&#8217; From Legalization Wave</a>
&#8220;This license is a huge step forward for DEMECAN and the entire industry," <a href="https://www.demecan.de/en/press-releases/demecan-becomes-the-first-german-company-to-receivecultivation-license-for-medical-cannabis-under-new-medcang/" target="_blank" rel="noreferrer noopener">stated</a> Dr. Adrian Fischer, physician and managing director responsible for cultivation at Demecan. "We are proud to be the first German company to take this step and look forward to providing our high-quality cannabis strains soon. Our goal is to further increase production and thus improve supply security, as there are currently manyshortages in patient care.&#8221;
<h2 class="wp-block-heading">Strong Sales</h2>
Since April 2024, DEMECAN has achieved strong revenue growth, underscoring the significance and impact of the new cannabis law.
&#8220;The significantly increased demand is reflected in our strong sales and shows that we are on the right track. The new cultivation permit not only allows us to meet the growing demand but also enables the sustainable development of our company,&#8221; said Dr. Philipp Goebel, managing director in charge of sales,
In April, at the <a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Benzinga Cannabis Capital Conference</a>, Dr. Constantin von der Groeben, a managing director of DEMECAN, <a href="https://www.benzinga.com/markets/cannabis/24/04/38283982/global-cannabis-strategies-post-german-legalization-exclusive-insights-from-curaleaf-gold-flora-">told the crowd</a> &#8220;there&#8217;s no stepping back&#8221; from Germany&#8217;s cannabis legalization. Recent changes in the medical marijuana prescription process and hemp laws confirm that the cannabis program in Germany is yet to boom.
<h2 class="wp-block-heading">Opportunities In Innovation And Research</h2>
Von der Groeben also previously <a href="https://www.benzinga.com/markets/cannabis/24/03/37423458/huge-benefits-for-medical-marijuana-patients-opportunities-for-innovation-research-industry-vets">told Benzinga</a> that in addition to recognizing the medical and economic benefits of cannabis, the reform ushers in opportunities for innovation, research and development.
&#8220;The recent legislative reforms in Germany mark a transformative chapter not only for DEMECAN but for the entire medical cannabis sector within the country. A crucial aspect of these reforms is the reclassification of cannabis from a narcotic to a prescription (Rx) drug,&#8221; he said, predicting that the market will show substantial growth in the first few years.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39830117/medical-marijuana-regulated-as-ibuprofen-is-one-of-the-biggest-breakthroughs-of-germanys-cannabi" target="_blank" rel="noreferrer noopener">Medical Marijuana Regulated As Ibuprofen Is One Of The Biggest Breakthroughs Of Germany&#8217;s Cannabis Law</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39730706/is-germany-poised-to-become-the-next-weed-epicenter-in-europe" target="_blank" rel="noreferrer noopener">Is Germany Poised To Become The Next Weed Epicenter In Europe?</a></li>
</ul>
Courtesy of&nbsp;Handatko&nbsp;via Shutterstock

Cannabis

Eurozone

TLRY

German Cannabis Producer DEMECAN Becomes First Company To Receive Cultivation License Under Legalization Program, Sees Strong Revenue Growth (Updated)

The Company will discuss its full revenue&nbsp;guidance&nbsp;for the&nbsp;third quarter&nbsp;of 2024 during its upcoming conference call.&nbsp;

Guidance

RMBS

Rambus Expects Q3 Licensing Billings Of $60M - $66M, Product Revenue Of $62M - $68M, Contract And Other Revenue Of $17M - $23M

CIBC analyst Allison Carson maintains Vizsla Silver (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VZLA#AMEX">VZLA</a>) with a Outperformer and raises the price target from C$3.5 to C$4.5.

VZLA

CIBC Maintains Outperformer on Vizsla Silver, Raises Price Target to C$4.5

Legal

CRWD

MSFT

Delta To Seek Compensation From Microsoft, CrowdStrike

Delta Hires Lawfirm Following Software Outage

Rambus Expects Strong Q3 Driven Again By Double-Digit Sequential Chip Growth

NewMarket Reports Q2 EPS Of $11.63, Up From $10.36 Last Year; Total Net Sales $710.228M, Up From $685.13M Last Year

Chesapeake Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHK#NASDAQ">CHK</a>) reported its second-quarter financial results Monday. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/07/n40021754/chesapeake-energy-corporation-reports-second-quarter-2024-results">details from the report.</a>&nbsp;
The Details: Chesapeake Energy reported quarterly earnings of 1 cent per share, a 98.44% decrease from earnings of 64 cents per share from the same period last year.
The company reported quarterly sales of $505 million, missing the analyst consensus estimate of $787.14 million by 35.84% and representing a 73.29% decrease from the same period last year.
Chesapeake&#8217;s net production in the second quarter was approximately 2.75 bcfe per day (100% natural gas), utilizing an average of eight rigs to drill 30 wells and place four wells on production while building an inventory of five drilled but uncompleted (DUCs) wells and 24 deferred turn in lines (TILs). Chesapeake is currently operating seven rigs and two completion crews, having dropped an additional rig in the Marcellus earlier in July.
Read Also: <a href="https://www.benzinga.com/news/24/07/39989347/whats-going-on-with-lululemon-stock">What&#8217;s Going On With Lululemon Stock?</a>
&#8220;We continue to execute our business as we prudently manage current market conditions and prepare for our pending combination with Southwestern. We remain focused on operational improvements and enhancing capital efficiency. The efforts of our team have positioned us to lower our 2024 capital and production expense guidance by $50 million and approximately 8%, respectively,&#8221; said Nick Dell&#8217;Osso, Chesapeake&#8217;s CEO. 
Outlook: Chesapeake Energy lowered its 2024 capital and production expense guidance approximately 4% and approximately 8%, respectively, primarily due to improved operational efficiency and year-over-year deflation.
CHK Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Chesapeake Energy shares are flat after-hours at $76.57 at the time of publication Monday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39984639/carbon-revolution-stock-races-on-chevrolet-corvette-zr1-wheels">Carbon Revolution Stock Races On Chevrolet Corvette ZR1 Wheels</a></li>
</ul>
Image:&nbsp;u_3u3n7wt5sr from Pixabay

After-Hours Center

Movers

Chesapeake Energy Posts Mixed Q2 Results: The Details

CIBC analyst Kevin Chiang maintains TFI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFII#NYSE">TFII</a>) with a Outperformer and raises the price target from $167 to $179.

TFII

CIBC Maintains Outperformer on TFI International, Raises Price Target to $179

German American Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GABC#NASDAQ">GABC</a>) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.62 by 11.29 percent. This is a 8 percent decrease over earnings of $0.75 per share from the same period last year.

GABC

German American Bancorp Q2 EPS $0.69 Beats $0.62 Estimate

https://asia.nikkei.com/Business/Finance/Japan-taps-brokerages-to-market-JGBs-abroad-as-BOJ-steps-back#:~:text=TOKYO%20%2D%2D%20Japan's%20Ministry%20of,purchasing%20program%2C%20Nikkei%20has%20learned

Bonds

Markets

'Japan taps brokerages to market JGBs abroad as BOJ steps back' - NIKKEI

PACCAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) has outperformed the market over the past 5 years by 3.78% on an annualized basis producing an average annual return of 17.02%. Currently, PACCAR has a market capitalization of $51.55 billion. 
Buying $1000 In PCAR: If an investor had bought $1000 of PCAR stock 5 years ago, it would be worth $2,164.37 today based on a price of $98.32 for PCAR at the time of writing.
<h3>PACCAR's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722286909_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

PCAR

Here's How Much $1000 Invested In PACCAR 5 Years Ago Would Be Worth Today

Ratings for DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for DexCom, revealing an average target of $107.6, a high estimate of $145.00, and a low estimate of $75.00. Experiencing a 25.83% decline, the current average is now lower than the previous average price target of $145.07. 
<img src="https://www.benzinga.com/files/images/story/2024/1722286893_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive DexCom is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$113.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$120.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$95.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$89.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$145.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$132.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Issie Kirby</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Neutral</td>
<td>$130.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to DexCom. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of DexCom compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of DexCom's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into DexCom's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DXCM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DexCom analyst ratings.</a>
<h2>Unveiling the Story Behind DexCom</h2>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>DexCom's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: DexCom displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 15.26%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: DexCom's net margin excels beyond industry benchmarks, reaching 14.29%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): DexCom's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.13% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): DexCom's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.16% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 1.07, DexCom faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DXCM

Demystifying DexCom: Insights From 15 Analyst Reviews

Throughout the last three months, 4 analysts have evaluated Virtus Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTS#NYSE">VRTS</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Virtus Inv, revealing an average target of $246.5, a high estimate of $267.00, and a low estimate of $208.00. Experiencing a 0.9% decline, the current average is now lower than the previous average price target of $248.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1722286885_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Virtus Inv among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$208.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$264.00</td>
<td>$267.00</td>
</tr>
<tr>
<td>Bill Kirk</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$247.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$267.00</td>
<td>$265.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Virtus Inv. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Virtus Inv compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Virtus Inv's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Virtus Inv's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VRTS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Virtus Inv analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Virtus Inv's Background</h2>
Virtus Investment Partners Inc provides investment management and related services to individuals and institutions. Its retail products include open-end mutual funds, closed-end funds, exchange-traded funds, and variable insurance funds. Geographically, the activities are carried out through the region of the U.S. and the group generates revenue through investment management fees, distribution and service fees and administration and shareholder service fees.
<h3>A Deep Dive into Virtus Inv's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Virtus Inv's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 12.22% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Virtus Inv's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 13.51%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Virtus Inv's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.44%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.83%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 2.5, Virtus Inv faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRTS

Navigating 4 Analyst Ratings For Virtus Inv

21 analysts have expressed a variety of opinions on Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $41.76, a high estimate of $56.00, and a low estimate of $26.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 14.43%. 
<img src="https://www.benzinga.com/files/images/story/2024/1722286876_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Roblox. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Handler</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Neutral</td>
<td>$42.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Nick McKay</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$46.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Andrew Uerkwitz</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$42.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Aaron Lee</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Outperform</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$41.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Eric Handler</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$56.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Ross Sandler</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$35.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Jason Tilchen</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Clark Lampen</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$46.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Clay Griffin</td>
<td>MoffettNathanson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Benjamin Black</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Matthew Cost</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$35.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Mike Hickey</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Nick McKay</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$46.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Eric Handler</td>
<td>Roth MKM</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Roblox. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Roblox compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Roblox's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Roblox's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RBLX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Roblox analyst ratings.</a>
<h2>All You Need to Know About Roblox</h2>
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or "experiences") for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises.
<h3>Unraveling the Financial Story of Roblox</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Roblox's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 22.27%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Communication Services sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Roblox's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -33.77%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Roblox's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -365.95%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Roblox's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -4.34% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 25.45, Roblox faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RBLX

Expert Ratings For Roblox

In the last three months, 4 analysts have published ratings on Ameris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABCB#NYSE">ABCB</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $68.5, a high estimate of $76.00, and a low estimate of $64.00. Marking an increase of 20.7%, the current average surpasses the previous average price target of $56.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1722286855_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Ameris by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$69.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Kevin Fitzsimmons</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Catherine Mealor</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Tyler Stafford</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$64.00</td>
<td>$52.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ameris. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ameris compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Ameris's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Ameris's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ABCB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ameris analyst ratings.</a>
<h2>Discovering Ameris: A Closer Look</h2>
Ameris Bancorp is a bank holding company that operates through Ameris Bank, its subsidiary. The company operates branches in Georgia, Alabama, Florida, and South Carolina. It offers traditional banking services such as business banking, personal banking, checking, savings, mobile banking, and others. The bank is organized into five segments: banking, retail mortgage, warehouse lending, SBA, and premium finance. The company generates most of its revenue from the banking segment. Ameris intends to acquire banks in its geographic region to increase its market share and expand beyond its current market.
<h3>Financial Insights: Ameris</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Ameris showcased positive performance, achieving a revenue growth rate of 16.5% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ameris's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 30.28% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Ameris's ROE excels beyond industry benchmarks, reaching 2.57%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Ameris's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.35% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Ameris's debt-to-equity ratio is below the industry average at 0.3, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABCB

Breaking Down Ameris: 4 Analysts Share Their Views

Global X U.S. Infrastructure Development UCITS ETF USD Acc

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

News

Latest news for (OTC:MRAEF) Stock